Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.
Cancer Chemother Pharmacol
; 79(2): 315-326, 2017 Feb.
Article
in En
| MEDLINE
| ID: mdl-28097385
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Sulfonamides
/
Thiadiazoles
/
Kinesins
/
Neoplasms
Type of study:
Clinical_trials
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Cancer Chemother Pharmacol
Year:
2017
Document type:
Article